Effects of a new cholecystokinin antagonist, TS-941, on experimental acute pancreatitis in rats

Pancreas

Volumn 17, Issue 3, 1998, Pages 289-294

  Wang, Youxue ^a   Naruse, Satoru ^a   Kitagawa, Motoji ^a   Ishiguro, Hiroshi ^a   Nakae, Yasuyuki ^a   Yoshikawa, Toshiyuki ^a   Hayakawa, Tetsuo ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cholecystokinin receptor antagonist; Experimental pancreatitis; Trypsinogen activation peptide (TAP); 2 macroglobulin trypsin complex

Indexed keywords

ALPHA 2 MACROGLOBULIN; AMYLASE; BENZODIAZEPINE DERIVATIVE; CERULETIDE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; ONO 3403; PANCREAS ENZYME; TAUROCHOLIC ACID; TRIACYLGLYCEROL LIPASE; TRYPSIN; TRYPSIN INHIBITOR; TRYPSINOGEN; TS 941; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CONTROLLED STUDY; DRUG EFFECT; ENZYME IMMUNOASSAY; HEMORRHAGIC PANCREATITIS; MALE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE;

EID: 0031695221     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-199810000-00011     Document Type: Article

References (21)

1. Evander A, Lundquist I, Ihse I. Influence of gastrointestinal hormones on the course of acute experimental pancreatitis. Hepatogastroenterology 1982;29:161-6.
2. Niederau C, Liddle RA, Ferrell LD, Grendell JH. Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. J Clin Invest 1986;78:1056-63.
3. Gorelick FS, Adler G, Kern HF. Cerulein-induced pancreatitis. In: G. WLVU, et al., eds. The pancreas: biology, pathophysiology, and disease, 2nd ed. New York: Raven Press, 1993:501-26.
4. Grendell JH. Clinical potentials of CCK antagonists. Experimental pancreatitis. In: Adler G. Beglinger C, eds. Cholecystokinin antagonists in gastroenterology: basic and clinical status, Berlin: Springer-Verlag, 1991:197-202.
5. McQuaid KR, Niederau C, Ferrell LD, Grendell JH. Effects of lorglumide alone or with atropine or gastrin on diet-induced acute hemorrhagic pancreatitis in mice. Pancreas 1988;3:607.
6. Oshiro G, Saluja A, Leli U, Sengupta A, Steer ML. Failure of a potent cholecystokinin antagonist to protect against diet-induced pancreatitis in mice. Pancreas 1989;6:739-43.
7. Gudgeon AM, Heath DI, Hurley P, et al. Trypsinogen activation peptides assay in the early prediction of severity of acute pancreatitis. Lancet 1990;335:4-8.
8. Nakae Y, Naruse S, Kitagawa M, Hirao S, Yamamoto R, Hayakawa T. Activation of trypsinogen in experimental models of acute pancreatitis in rats. Pancreas 1995;10:306-13.
9. 2-macroglobulin trypsin complex with new synthetic substrate. Clin Chem 1989;35:2169-72.
10. 2-macroglobulm trypsin complex in pancreatic diseases using a colorimetric assay with a synthetic substrate. Jpn J Gastroenterol 1991;88:2853-60 (in Japanese).
11. Sobajima H, Hayakawa T, Kondo T, et al. Monitoring serum tryptic activity and effect of trypsin inhibitor on rat acute pancreatitis. Digestion 1994;55:90-6.
12. Beechey-Newman N, Simpson K, Sumar N, Jehanli A, Hermon-Taylor J. Trypsinogen activation peptide (TAP) ELIZA demonstrates self-limiting trypsinogen activation in CCK-hyperstimulation pancreatitis in dogs. Pancreas 1993;8:748.
13. Karanjia ND, Widdison AL, Jehanli A, Hermon-Taylor J, Reber HA. Assay of trypsinogen activation in the cat experimental model of acute pancreatitis. Pancreas 1993;8:189-95.
14. Saluja AK, Saluja M, Printz H, Zavertnik A, Sengupta A, Steer ML. Experimental pancreatitis is mediated by low-affinity cholecystokinin receptors that inhibit digestive enzyme secretion. Proc Nat Acad Sci USA 1989;86:8968-71.
15. Niederau C, Ferrell LD, Grendell JH. Caerulein-induced acute necrotizing pancreatitis in mice: protective effects of proglumide, benzotript, and secretin. Gastroenterology 1985;88:1192-204.
16. Murayama KM, Drew JB, Nahrwold DL, Joehl RJ. Cholecystokinin antagonist prevents hyperamylasemia and improves pancreatic exocrine function in caerulein-induced acute pancreatitis. Pancreas 1990;5:439-44.
17. Tani M, Okabayashi Y, Nakamura T, Fujii M, Itoh H, Otsuki M. Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models. Pancreas 1990;5:284-90.
18. Garcia-Montero AC, Manso MA, Rodriguez AI, De Dios I. Therapeutic and protective effect of subcutaneous injection of L-364,718 on cerulein-induced acute pancreatitis. Pancreas 1994;9:309-15.
19. Adler G, Hahn C, Kern HF, Rao KN. Cerulein-induced pancreatitis in rats: increased lysosomal enzyme activity and autophagocytosis. Digestion 1985;32:10-18.
20. Bialek R, Willemer S, Arnold R, Adler G. Evidence of intracellular activation of serine proteases in acute cerulein-induced pancreatitis in rats. Scand J Gastroenterol 1991;26:190-6.
21. Fernandez-del Castillo C, Schmidt J, Rattner DW, et al. Generation and possible significance of trypsinogen activation peptide in experimental acute pancreatitis in rats. Pancreas 1992;7:263-70.